___

• Aronsson T. et. al. (2001) ―The Impact of Generic Drug Competition on
• Brand Name Market Shares—Evidence from Micro Data‖, Review of
• Industrial Organization. 19: 425–435. 2.
• Bergman M. A. and Rudholm N. (2003) ―The Relative Importance of
• Actual and Potential Competition: Empirical Evidence from the
• Pharmaceuticals Market‖, Journal of Industrial Economics. 51(4): 455– 467. 3.
• Brekke K. R. et. al. (2009) ―Regulation and Pricing of Pharmaceuticals:
• Reference Pricing or Price Cap Regulation‖, European Economic
• Danzon P. M. (2001) ―Reference Pricing: Theory and Evidence‖ In López-Casasnovas, G., and Jonsson, B. (ed.), Reference Pricing and Pharmaceutical Policy: Perspectives on Economics and Innovation, pp: 86-126. Springer, Barcelona.
• Danzon, P.M. and Liu H. (1996) ―RP and physician drug budgets: The German Experience in Controlling Pharmaceutical Expenditures", Working Paper, The Wharton School.
• Dukes M. N. (2002) ―Accountability of the Pharmaceutical Industry‖, The Lancet. 360: 1682-1684.
• Forbes (2008) www.forbes.com
• Frank R. G. and Salkever D. S. (1997) ―Generic Entry and the Market for Pharmaceuticals‖, Journal of Economics & Management Strategy. 6: 75–90.
• Grabowski H. (2002) Patents, ―Innovation and Access to New Pharmaceuticals‖, Journal of International Economics Law. 5(4): 849 - 860.
• Grabowski H. and Wang R. (2006) ―The Quantity and Quality of Worldwide New Drug Introductions: 1982-2003‖, Health Affairs. 25(2): 452-460.
• Grabowski H. G. and Vernon J. M. (1992) ―Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act‖, Journal of Law and Economics. 35(2): 331-350.
• Huber M. and Orosz E. (2003) ―Health Expenditure Trends in the OECD Countries, 1990–2001‖, Health Care Financing Review. 25(1): 1–22
• Ioannides-Demos L. L. et. al. (2002) ―Reference-based Pricing Schemes: Effect on Pharmaceutical Expenditure, Resource Utilization and Health Outcomes‖, PharmacoEconomics. 20(9): 577-591.
• IMS (2008) IMS Health 2008.
• Kaló Z. et. al. (2007) ―Does Therapeutic Reference Pricing Always Result in Cost-Containment? The Hungarian Evidence‖, Health Policy. 80: 402– 412.
• Kildemoes et. al. (2006) ―The Impact of Population Ageing on Future Danish Drug Expenditure‖, Health Policy. 75: 298-311.
• King D. R. and Kanavos P. (2002) ―Encouraging the Use of Generic Medicines: Implications for Transition Economies‖, Croatian Medical Journal. 43: 462–469.
• Lichtenberg F. R. (1996) ―Do (More and Better) Drugs Keep to People Out of Hospital‖, The American Economic Review. 86(2): 384-388.
• López-Casasnovas G. and Puig-Junoy J. (2000) ―Review of the Literature on Reference Pricing‖, Health Policy. Vol. 54: 87–123.
• López-Casasnovas G. and Puig-Junoy J. (2005) ―Reference Pricing as a Pharmaceutical Reimbursement Mechanism‖, The Public Financing of Pharmaceuticals. In J. Puig-Junoy (ed.), pp: 103-123. Edward Elgar, Cheltenham.
• Maynard A. and Bloor, K. (2003) ―Dilemmas in Regulation of the Market for Pharmaceuticals‖, Health Affairs. 22(3): 1-11.
• Miller R. D. Jr. and French H. E. (2000) ―Is There a Link Between Pharmaceutical Consumption and Improved Health in OECD Countries?‖, Pharmacoeconomics. 18: 33–45.
• OECD (2008a) Health a Glance 2008, OECD, Paris.
• OECD (2008b) Pharmaceutical Pricing in a Global Market, OECD, Paris.
• Paris V. and Docteur E. (2006) Pharmaceutical Pricing and Reimbursement Policies in Canada, OECD Health Working Paper No. 24, OECD, Paris.
• Paris V. and Docteur E. (2008) Pharmaceutical Pricing and Reimbursement Policies in Germany, OECD Health Working Papers, No. 39, OECD, Paris.
• Pavcnik N. (2002) ―Do Pharmaceutical Prices Respond to Potential Patient Out-of-Pocket Expenses?‖, RAND Journal of Economics. 33 (3): 469–487.
• Pharmaceutical Pricing and Reimbursement Information (2008) Germany Pharma Profile, PPRI 2008.
• Pharmaceutical Research and Manufacturers of America (2005) Pharmaceutical Industry Profile 2008, Washington, DC.
• Puig-Junoy J. (2004) ―Incentives and Pharmaceutical Reimbursement Reforms in Spain‖, Health Policy. 67: 149–165.
• Puig-Junoy J. (2007) ―The Impact of Generic Reference Pricing Interventions in the Statin Market‖, Health Policy. 84: 14-29.
• Schneeweiss S. (2007) ―Reference Drug Programs: Effectiveness and Policy Implications‖, Health Policy. 81: 17–28.
• Simoens S. and Coster De S. (2006a) ―Potential Savings from Increased Substitution of Generic for Originator Medicines in Europe‖, Journal of Generic Medicines. 4(1): 43-45.
• Simoens S. and Coster De S. (2006b) ―Sustaining generic medicines markets in Europe‖, Journal of Generic Medicines. Vol. 3 (1): 257-268
• Sood N. et. al. (2009) ―The Effect of Regulation on Pharmaceutical Revenues: Experience In Nineteen Countries‖, Health Policy. 28(1): 125- 137.
• Zweifel P. and Crivelly L. (1996) ―Price Regulation of Drugs: Lessons from Germany‖, Journal of Regulatory Economics. 10: 257–273.